Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine.
about
Pandemic Threat Posed by Avian Influenza A VirusesVaccines and antiviral drugs in pandemic preparednessNeuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cellsInfluenza: emergence and controlAntiviral drugs for viruses other than human immunodeficiency virusIon channel activity of influenza A virus M2 protein: characterization of the amantadine blockStructure of influenza hemagglutinin in complex with an inhibitor of membrane fusionInhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomersTreatment of influenza with neuraminidase inhibitors: virological implicationsRWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenzaComparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza virusesInhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compoundsA novel antiviral agent which inhibits the endonuclease of influenza virusesOral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion proteinStructure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivoCharacterization of potent fusion inhibitors of influenza virusIdentification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput ScreeningPassive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.Role of combination antiviral therapy in pandemic influenza and stockpiling implications.Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza A endonuclease.Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance.Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase.Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium.Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replicationIn vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.Influenza virus resistance to antiviral agents: a plea for rational use.Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein.Virus-vectored influenza virus vaccines.Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homesAdamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations.Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.Coupling high-throughput genetics with phylogenetic information reveals an epistatic interaction on the influenza A virus M segment.Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen.Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice
P2860
Q22299330-A06CC0FD-E72A-40A1-98E0-65EE995296C4Q22305646-1AC363CD-436C-4047-AC88-8B175B0E6037Q24559989-5943D0CE-30BF-4A69-ABA7-764CDEAE1313Q24562911-CFC8B843-22FB-486E-A18A-9998B8A0DAFFQ24635330-E0429E27-C8F9-4E14-A025-DE6E62D2BADBQ24655972-94E11FAD-5EE0-4EF2-979E-588F642C0119Q24656213-563FA7FF-F3F9-4675-930B-BDFBBE140735Q24675029-0CE712D0-3B60-4D96-8158-3DCF349423E6Q28344588-EE1312B6-0B4B-4298-B1B1-9573FC5648F2Q28344592-312B4C1D-3487-4F6C-97E9-6D68A922E570Q28353147-631932B7-B35D-41C1-801B-43FBA4E4107CQ28368059-CA90B25A-F507-4672-AE92-CF51D0E27D9BQ28378972-84506287-87DD-484E-A363-5F95B54F9812Q28379409-48F88DDB-1A50-49EA-9BCB-76A818E01C68Q28471835-76B73A04-3346-4D69-8732-AD61F02DC435Q28476470-A2D70576-FEC5-4F8D-A10B-36F5DA2C17D3Q28544971-4DF72367-AFF2-4E7D-A685-C80798EF5DF5Q28830304-CE0A6AC6-2DF5-48E9-A696-3C9587DF8829Q30353490-6D36BAAA-355F-46D8-9084-AC807AE5C69FQ30359766-DF1C6642-F159-4E0B-9E0E-E81CB9CD71ACQ30366846-34B4B4C5-31BC-4F46-8194-7913D3A44D62Q30379095-165B6882-A036-4A0F-9F85-4C309EE3F3A5Q30379476-108717D7-0723-4F42-B0FD-D5217D88EA25Q30382312-7BF70236-262F-494E-8490-1E0648BBA234Q30414976-91D09E90-A60C-413D-A13E-A18ABF5C78FAQ30426551-16828D43-AD73-4877-9ECE-F36A12D4E48DQ30447033-A5EA6A67-F6AE-4468-991A-076341F56E92Q30453074-349D81CF-B4F2-42D8-8B35-03DE582B1F25Q30453278-5D46B927-A744-4122-A9D7-B77B78EAA425Q33701528-2F7BB7CB-BE91-4995-B5DB-277028E0CEB5Q33826335-65B149A8-974E-48BC-8F0F-106194494CFDQ34099149-9B698083-0BF4-467B-92A5-D344B6BB2C88Q34102268-F19A7B5B-5FA8-484A-8270-8A94B513BF6BQ34405859-4447E9EF-6F2F-4AEC-8560-2CE6DC61B31BQ35119366-32997768-A0C4-49E8-80F6-1E98FC4D0BABQ35175284-A33A60C6-8EB7-4888-B3E8-62E74D12A3D0Q35698322-BE38647D-AA12-43E6-99D4-080025256C88Q35891196-211BC3F5-8AC8-4E4D-8964-1E8B825FD9C4Q36243643-8D83C3D1-DFB5-4123-A465-232BB20E50D5Q36949482-A4CEB9A0-0F43-41CF-9C47-1B1AF8B2CBF3
P2860
Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Emergence and transmission of ...... to amantadine and rimantadine.
@ast
Emergence and transmission of ...... to amantadine and rimantadine.
@en
type
label
Emergence and transmission of ...... to amantadine and rimantadine.
@ast
Emergence and transmission of ...... to amantadine and rimantadine.
@en
prefLabel
Emergence and transmission of ...... to amantadine and rimantadine.
@ast
Emergence and transmission of ...... to amantadine and rimantadine.
@en
P1476
Emergence and transmission of ...... to amantadine and rimantadine.
@en
P2093
P304
P577
1992-01-01T00:00:00Z